Nisin
Antimicrobial / Food SafetyAlso known as: Nisin A, Nisaplin
Mechanism
The most commercially successful antimicrobial peptide in the world. Naturally produced by the bacterium Lactococcus lactis (found in milk). FDA-approved as GRAS for food preservation since 1988 — used in cheese, canned foods, and processed meats. Kills gram-positive bacteria by punching holes in their membranes. Now being studied for clinical applications against MRSA and biofilm infections.
Technical detail
Lantibiotic (lanthionine-containing antibiotic) — 34-amino acid post-translationally modified peptide with 5 intramolecular thioether (lanthionine and methyllanthionine) rings. Dual killing mechanism: (1) Binds lipid II (peptidoglycan precursor) with high affinity via N-terminal rings A/B, sequestering it from cell wall synthesis. (2) C-terminal portion inserts into bacterial membrane, forming 2-nm pores (lipid II-dependent) that cause rapid ion efflux and membrane depolarization. Active against gram-positive bacteria including MRSA, VRE, Listeria, Clostridium. MIC: 1-10 µg/mL for most gram-positives. Resistance is rare due to lipid II target conservation. Being explored for treatment of mastitis, skin infections, and as a biofilm disruptor.
Effects
ANTIMICROBIAL MECHANISM: Lantibiotic (lanthionine-containing antibiotic) produced by Lactococcus lactis. Dual mechanism: (1) Binds lipid II (the same peptidoglycan precursor target as vancomycin) with high affinity via its A/B rings, sequestering it and blocking cell wall synthesis. (2) Uses lipid II as a docking molecule to insert into the membrane, forming 2-nm pores composed of 8 nisin + 4 lipid II molecules. These pores cause rapid efflux of ions and small molecules, membrane depolarization, and cell death within seconds-minutes. The combination of cell wall AND membrane disruption makes nisin extremely potent and rapidly bactericidal. SPECTRUM: Broad Gram-positive activity: Listeria monocytogenes (primary food safety target, MIC 0.5-8 μg/mL), Staphylococcus aureus (including MRSA), Streptococcus spp., Clostridium spp. (including C. botulinum spores — nisin prevents outgrowth), Bacillus spp., Enterococcus spp. (including VRE). Activity against Gram-negative bacteria is limited to damaged outer membranes or in combination with chelators (EDTA) that destabilize the outer membrane. FOOD SAFETY APPLICATIONS: FDA GRAS (Generally Recognized As Safe) since 1988. Approved as food preservative (E234) in >50 countries. Primary uses: dairy products (cheese, processed cheese), canned foods, meat products, beverages. Effective against Listeria in ready-to-eat foods. Prevents botulinum toxin production in canned/vacuum-packed foods. RESISTANCE: Nisin resistance mechanisms include: cell wall modifications (D-alanylation of teichoic acids via dlt operon), cell membrane composition changes (increased DPC/DMPG ratio), nisin-specific immunity protein (NisI) and efflux (NisFEG) in producer strains, lipid II modifications. Resistance development rate is low in food applications. PHARMACOKINETICS (for potential clinical use): Rapidly degraded by digestive proteases (oral bioavailability essentially zero — relevant for food safety, not systemic therapy). In vitro, nisin is active at nanomolar concentrations. Stability: active at pH 2-6 (acidic conditions, ideal for food), rapidly inactivated above pH 7. Heat-stable during food processing (autoclave stable at pH <4). EMERGING CLINICAL APPLICATIONS: Nisin shows activity against MRSA, VRE, and other MDR Gram-positives (in vitro). Being explored for topical wound infections, skin infections, mastitis (veterinary), oral care (dental biofilms), and potentially as a systemic antibiotic if delivery challenges can be solved. Anti-biofilm activity demonstrated in vitro.
Practitioner Guide
CLINICAL PEARLS — FOOD SAFETY AND EMERGING CLINICAL PERSPECTIVE: FOOD INDUSTRY USE: Nisaplin® (commercially available nisin preparation) — typically 2.5% pure nisin in NaCl/milk solids carrier. Usage levels: 100-500 IU/g (or 2.5-12.5 ppm pure nisin) in food products. Effective against Listeria at concentrations as low as 100 IU/g in many food matrices. For processed cheese: 200-500 IU/g prevents Clostridium and Listeria growth. For canned vegetables: 100-200 IU/g extends shelf life and prevents spoilage. SYNERGIES IN FOOD: Nisin + EDTA — EDTA chelates divalent cations in Gram-negative outer membrane, allowing nisin access. This extends nisin activity to E. coli, Salmonella (food safety relevant). Nisin + pediocin — dual bacteriocin approach for enhanced anti-Listeria activity. Nisin + high-pressure processing (HPP) — synergistic killing (emerging food technology). Nisin + organic acids (lactic, citric) — enhanced activity at lower pH. EMERGING CLINICAL APPLICATIONS: Topical nisin formulations for MRSA wound infections — proof-of-concept studies show efficacy in animal wound models. Nisin-containing dental products for caries prevention and periodontal disease (disrupts Streptococcus mutans biofilms). Veterinary: nisin-based intramammary infusions for bovine mastitis (commercially available in some markets). Nisin-coated medical devices (catheters, implants) to prevent biofilm formation — in development. LIMITATIONS FOR SYSTEMIC CLINICAL USE: (1) Protease degradation — nisin is rapidly degraded by trypsin, chymotrypsin, and pepsin. Systemic use would require encapsulation or chemical modification. (2) Serum inactivation — nisin activity is reduced in serum due to protein binding and lipid interactions. (3) Narrow pH optimum — most active at acidic pH, less active at physiological pH 7.4. (4) Short half-life in vivo. Solutions being explored: PEGylation, liposomal encapsulation, D-amino acid analogs, cyclic variants. SAFETY: Extremely well-characterized safety profile from decades of food use. ADI (Acceptable Daily Intake) set by WHO/FAO at 0-33,000 IU/kg body weight. No known adverse effects at food-use concentrations. Allergenic potential: extremely low (rapidly digested). Not classified as an antibiotic for regulatory purposes in food applications.
Research Summary
TIER 1 (Gold Standard): FDA GRAS determination (1988, reaffirmed). EFSA opinion on nisin as food additive (E234) — comprehensive safety assessment. WHO/FAO JECFA evaluation — established ADI. Multiple food safety RCTs demonstrating efficacy against Listeria in various food matrices. TIER 2 (Strong): Wiedemann et al., 2001 — mechanism of action: lipid II binding and pore formation (Journal of Biological Chemistry, PMID: 11278587). Breukink et al., 1999 — nisin uses lipid II as docking molecule for pore formation (Science, PMID: 10557147 — landmark mechanistic paper). Cotter et al., 2005 — comprehensive review of lantibiotics (Nature Reviews Microbiology, PMID: 16205711). DrugBank DB14010. Extensive food microbiology literature. TIER 3 (Moderate): Clinical feasibility studies for topical wound applications. Veterinary mastitis treatment data. Dental biofilm studies. Conference presentations at ASM, IAFP (International Association for Food Protection). International regulatory dossiers from >50 countries. Industrial application data from Danisco/DuPont (Nisaplin manufacturer). KEY FINDINGS: (1) Nisin has a unique and well-characterized dual mechanism (lipid II + pore formation). (2) Decades of safe food use provide an unparalleled safety record. (3) Activity against MRSA, VRE, and other MDR organisms makes it clinically interesting. (4) Delivery challenges (protease sensitivity, pH, serum inactivation) limit systemic clinical use. (5) Topical/mucosal applications are the most feasible clinical translation. GAPS: Systemic delivery solutions. Clinical trials for wound infections, dental applications. Resistance development surveillance in food isolates. Whether food-use nisin contributes to antibiotic resistance (controversial). Engineered nisin variants with improved stability and broader spectrum. ACTIVE TRIALS: Preclinical studies on nisin-coated medical devices. Veterinary mastitis trials. Dental product development.